Skip to main content

Market Overview

Vetr Urges Buy On Antares Post-Correction

Share:

The Vetr crowd on Monday upgraded its rating on Antares Pharma Inc (NASDAQ: ATRS) from 3 stars (Hold), issued four days ago, to 5 stars (Strong Buy). Crowd sentiment at the time of the upgrade was unanimously positive, with 100 percent of Vetr user ratings bullish.

The Vetr upgrade comes as share price in the biotech company has corrected after spiking to a more than three-year high of 3.89 near the start of the month when it delivered strong revenue in its second-quarter earnings report. Most of the correction occurred after the company reported a negative note from the FDA on deficiencies in its XYOSTED NDA filing. By the close of Monday's session, Antares was trading at $2.10.

See how crowdsourced ratings could help you time the market.

Currently, the Vetr crowd's average price target for Antares is up at $3.69, which is above the average analyst price target of $3.10. Less than 2 percent of Vetr users are holding $ATRS in their watch-lists.

Latest Ratings for ATRS

DateFirmActionFromTo
May 2020HC Wainwright & Co.MaintainsBuy
Mar 2020Raymond JamesMaintainsStrong Buy
Mar 2019Raymond JamesMaintainsStrong BuyStrong Buy

View More Analyst Ratings for ATRS
View the Latest Analyst Ratings

 

Related Articles (ATRS)

View Comments and Join the Discussion!

Posted-In: VetrBiotech Upgrades Crowdsourcing Analyst Ratings General

Latest Ratings

StockFirmActionPT
SHNWFMorgan StanleyUpgrades
ICLRTruist SecuritiesUpgrades280.0
MNSTEvercore ISI GroupUpgrades
USPHBarrington ResearchDowngrades
BYNDCanaccord GenuityMaintains155.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com